Lantheus Announces Presentation Featuring PYLARIFY® (Piflufolastat F18) at the 2022 ASCO GU Meeting

NORTH BILLERICA, Mass., Feb. 10, 2022 -- Lantheus Holdings, Inc. , an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and... | February 10, 2022

Related Keywords

United States ,New Jersey ,Massachusetts ,North Billerica ,Sweden ,Maryland ,Canada ,San Francisco ,California ,American ,Michael Gorin ,Mark Kinarney ,Bausch Health Companies Inc ,Lantheus Medical Imaging Inc ,Progenics Pharmaceuticals Inc ,Corporate Communications ,Lantheus Holdings Inc ,Urology Associates ,Clinical Oncology Genitourinary ,Poster Session ,Prostate Cancer ,Standardized Uptake Value ,Results Stratified ,Gleason Score ,Full Prescribing ,Lantheus Holdings ,Lantheus Medical Imaging ,Progenics Pharmaceuticals ,Find Fight ,Perflutren Lipid Microsphere ,Injectable Suspension ,Bausch Health Companies ,Nc Stock Exchange ,News ,Information ,Press Release ,North ,022 ,Lantheus ,N ,Stablished ,Leader ,End ,Bully ,Ntegrated ,Provider ,Ommitted ,O ,Nnovative ,Maging ,Argeted ,Herapeutics Lnth Us5165441032 ,